The alterations of bile acids in rats with high-fat diet/streptozotocin-induced type 2 diabetes and their negative effects on glucose metabolism
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ogurtsova, 2017, IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040, Diabetes Res. Clin. Pract., 128, 40, 10.1016/j.diabres.2017.03.024
Kretowski, 2016, Genomics and metabolomics in obesity and type 2 diabetes, Journal of diabetes research, 2016, 10.1155/2016/9415645
Tahrani, 2011, Management of type 2 diabetes: new and future developments in treatment, Lancet (London, England), 378, 182, 10.1016/S0140-6736(11)60207-9
Park, 2015, A metabolomic approach to understanding the metabolic link between obesity and diabetes, Mol. Cells, 38, 587, 10.14348/molcells.2015.0126
Merino, 2017, A decade of genetic and Metabolomic contributions to type 2 diabetes risk prediction, Curr. Diab. Rep., 17, 135, 10.1007/s11892-017-0958-0
Goodpaster, 2017, Metabolic flexibility in health and disease, Cell Metab., 25, 1027, 10.1016/j.cmet.2017.04.015
Klein, 2016, Metabolomics and type 2 diabetes: translating basic research into clinical application, J. Diabetes Res., 2016, 10.1155/2016/3898502
Sas, 2015, Metabolomics and diabetes: analytical and computational approaches, Diabetes, 64, 718, 10.2337/db14-0509
Molinaro, 2018, Role of bile acids in metabolic control, Trends Endocrinol Metab, 29, 31, 10.1016/j.tem.2017.11.002
Karhus, 2017, Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: a review, Diabetes Obes. Metab., 19, 1214, 10.1111/dom.12946
Shapiro, 2018, Bile acids in glucose metabolism in health and disease, 215, 383
Thomas, 2008, Targeting bile-acid signalling for metabolic diseases, Nat. Rev. Drug Discov., 7, 678, 10.1038/nrd2619
de Boer, 2018, New insights in the multiple roles of bile acids and their signaling pathways in metabolic control, Curr. Opin. Lipidol., 10.1097/MOL.0000000000000508
Chavez-Talavera, 2017, Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease, Gastroenterology, 152, 1679, 10.1053/j.gastro.2017.01.055
Renga, 2010, The bile acid sensor FXR regulates insulin transcription and secretion, Biochim. Biophys. Acta, 1802, 363, 10.1016/j.bbadis.2010.01.002
Haeusler, 2013, Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids, Diabetes, 62, 4184, 10.2337/db13-0639
Li, 2012, Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity, J. Biol. Chem., 287, 1861, 10.1074/jbc.M111.305789
Trauner, 2010, Bile acids as regulators of hepatic lipid and glucose metabolism, Dig. Dis., 28, 220, 10.1159/000282091
Scherer, 2016, Obesity, diabetes, and cardiovascular diseases: a compendium, Circ. Res., 118, 1703, 10.1161/CIRCRESAHA.116.308999
Eckel, 2011, Obesity and type 2 diabetes: what can be unified and what needs to be individualized?, J. Clin. Endocrinol. Metab., 96, 1654, 10.1210/jc.2011-0585
Riobo Servan, 2013, Obesity and diabetes, Nutr. Hosp., 28, 138
Yorek, 2016, Alternatives to the Streptozotocin-diabetic rodent, Int. Rev. Neurobiol., 127, 89, 10.1016/bs.irn.2016.03.002
Liu, 2016, Left ventricular deformation associated with cardiomyocyte Ca(2+) transients delay in early stage of low-dose of STZ and high-fat diet induced type 2 diabetic rats, BMC Cardiovasc. Disord., 16
Zaborska, 2018, Rethinking bile acid metabolism and signaling for type 2 diabetes treatment, Curr. Diab. Rep., 18
Ma, 2018, Progress in metabonomics of type 2 diabetes mellitus, Molecules (Basel, Switzerland), 23, 10.3390/molecules23071834
Wewalka, 2014, Fasting serum taurine-conjugated bile acids are elevated in type 2 diabetes and do not change with intensification of insulin, J. Clin. Endocrinol. Metab., 99, 1442, 10.1210/jc.2013-3367
Brufau, 2010, Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism, Hepatology (Baltimore, Md), 52, 1455, 10.1002/hep.23831
Vincent, 2013, Higher circulating bile acid concentrations in obese patients with type 2 diabetes, Ann. Clin. Biochem., 50, 360, 10.1177/0004563212473450
Prawitt, 2011, Bile acid metabolism and the pathogenesis of type 2 diabetes, Curr. Diab. Rep., 11, 160, 10.1007/s11892-011-0187-x
Brown, 2016, Bile acid metabolism, 359
Hofmann, 2008, Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cellular and molecular life sciences, CMLS, 65, 2461, 10.1007/s00018-008-7568-6
Firneisz, 2014, Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?, World J. Gastroenterol., 20, 9072
Zhao, 2018, Risk factors associated with nonalcohol fatty liver disease and fibrosis among patients with type 2 diabetes mellitus, Medicine (Baltimore), 97
Tian, 2017, Effects of ginsenoside Rg1 on glucose metabolism and liver injury in streptozotocin-induced type 2 diabetic rats, Genet. Mol. Res., 16, 10.4238/gmr16019463
Baig, 2001, Liver disease and diabetes mellitus, Clin. Lab. Med., 21, 193
Thakkar, 2017, Effect of liver disease on hepatic transporter expression and function, J. Pharm. Sci., 10.1016/j.xphs.2017.04.053
Chow, 2017, The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Mol. Asp. Med., 10.1016/j.mam.2017.04.004
Zhu, 2011, Tissue-specific function of farnesoid X receptor in liver and intestine, Pharm. Res., 63, 259, 10.1016/j.phrs.2010.12.018
Kim, 2007, Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine, J. Lipid Res., 48, 2664, 10.1194/jlr.M700330-JLR200
de Aguiar Vallim, 2013, Pleiotropic roles of bile acids in metabolism, Cell Metab., 17, 657, 10.1016/j.cmet.2013.03.013
Li, 2013, Nuclear receptors in bile acid metabolism, Drug Metab. Rev., 45, 145, 10.3109/03602532.2012.740048
Staudinger, 2013, Nuclear-receptor-mediated regulation of drug- and bile-acid-transporter proteins in gut and liver, Drug Metab. Rev., 45, 48, 10.3109/03602532.2012.748793
Fang, 2015, Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance, Nat. Med., 21, 159, 10.1038/nm.3760
Sarenac, 2018, Bile acid synthesis: from nature to the chemical modification and synthesis and their applications as drugs and nutrients, Front. Pharmacol., 9
Ridlon, 2014, Bile acids and the gut microbiome, Curr. Opin. Gastroenterol., 30, 332, 10.1097/MOG.0000000000000057
Gu, 2017, Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment, Nat. Commun., 8
Tilg, 2014, Microbiota and diabetes: an evolving relationship, Gut, 63, 1513, 10.1136/gutjnl-2014-306928
Lynch, 2016, The human intestinal microbiome in health and disease, N. Engl. J. Med., 375, 2369, 10.1056/NEJMra1600266
Sohail, 2017, Role of the gastrointestinal tract microbiome in the pathophysiology of diabetes mellitus, J. Diabetes Res., 2017, 10.1155/2017/9631435
Gonzalez-Regueiro, 2017, The role of bile acids in glucose metabolism and their relation with diabetes, Ann. Hepatol., 16, 16
Kaska, 2016, Improved glucose metabolism following bariatric surgery is associated with increased circulating bile acid concentrations and remodeling of the gut microbiome, World J. Gastroenterol., 22, 8698, 10.3748/wjg.v22.i39.8698
Trabelsi MS, Lestavel S, Staels B, Collet X. Intestinal bile acid receptors are key regulators of glucose homeostasis. Proc. Nutr. Soc. 2016:1–11, https://doi.org/10.1017/s0029665116002834.
Duran-Sandoval, 2004, Glucose regulates the expression of the farnesoid X receptor in liver, Diabetes, 53, 890, 10.2337/diabetes.53.4.890
van Nierop, 2017, Clinical relevance of the bile acid receptor TGR5 in metabolism, The lancet Diabetes & endocrinology, 5, 224, 10.1016/S2213-8587(16)30155-3
Thomas, 2009, TGR5-mediated bile acid sensing controls glucose homeostasis, Cell Metab., 10, 167, 10.1016/j.cmet.2009.08.001
Chavez-Talavera, 2017, Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia and NAFLD, Gastroenterology, 10.1053/j.gastro.2017.01.055
Lee, 2017, Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes, 22, 15